Loading…
BioAge Labs, Inc. is projected to rise to $29.85 by 2027, a +23% move from its current price of $24.34. BIOA is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $23.55 | $24.35 | $25.18 | +0.05% |
| Jul 15 | $23.23 | $24.36 | $25.54 | +0.09% |
| Jul 16 | $23.00 | $24.37 | $25.83 | +0.14% |
| Jul 17 | $22.80 | $24.39 | $26.08 | +0.19% |
| Jul 18 | $22.64 | $24.40 | $26.29 | +0.23% |
| Jul 19 | $22.48 | $24.41 | $26.50 | +0.28% |
| Jul 20 | $22.35 | $24.42 | $26.68 | +0.32% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $22.35 | $24.42 | $26.68 | +0.32% |
| Week 2 | $21.61 | $24.50 | $27.77 | +0.65% |
| Week 3 | $21.08 | $24.58 | $28.66 | +0.98% |
| Week 4 | $20.65 | $24.66 | $29.44 | +1.30% |
| Week 5 | $20.29 | $24.74 | $30.16 | +1.63% |
| Week 6 | $19.97 | $24.82 | $30.84 | +1.96% |
| Week 7 | $19.69 | $24.90 | $31.48 | +2.29% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. Its work leverages a technology platform and differentiated human datasets to identify targets based on insights into molecular changes that drive aging.
BioAge was incorporated in 2015 and is headquartered in Emeryville, California.
Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and it develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has a collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc.
was incorporated in 2015 and is headquartered in Emeryville, California.
BioAge Labs, Inc. (BIOA) is a healthcare company focused on metabolic diseases. Its current price is $23.76 with a market cap of $1.06B and a rank of 2503.
The near-term price outlook shows a neutral stance for 2026, with an average forecast of $23.76 and a range from $12.62 to $31.29, indicating uncertainty around near-term motion.
Looking further out, the forecast envisions meaningful upside in coming years, with the 2030 average at $61.35, the 2040 average at $182.07, and the 2050 average at $381.42, corresponding to ROIs of 158.2%, 666.3%, and 1505.3% respectively and a bullish sentiment across these horizons.
A major floor 50.6% below — a decisive break under it would weaken the trend.
The nearest floor, 36.4% below — buyers have tended to step in here.
The nearest ceiling, 3.1% above — a clean break opens room to run.
A major ceiling 28.4% above — clearing it would confirm fresh momentum.
Key BIOA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BIOA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $24.42 | Sell | $24.39 | Sell |
| MA 10 | $24.47 | Sell | $23.95 | Buy |
| MA 20 | $22.48 | Buy | $22.59 | Buy |
| MA 50 | $19.15 | Buy | $20.33 | Buy |
| MA 100 | $19.04 | Buy | $18.69 | Buy |
| MA 200 | $15.33 | Buy | $16.09 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 64.05 | Neutral |
| Stoch RSI (14) | 6.05 | Buy |
| CCI (20) | 60.86 | Neutral |
| Williams %R (14) | -20.94 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | 9.05 | Buy |
| Bollinger %B (20,2) | 0.69 | Neutral |
| Stochastic %K (14) | 79.06 | Neutral |
| TRIX (15) | 1.36 | Buy |
| Awesome (5,34) | 4.43 | Buy |
| Ultimate (7,14,28) | 56.82 | Neutral |
| Momentum (10) | 1.72 | Buy |
| Aroon Osc (25) | 60.00 | Buy |
| Hull MA (9) | 24.26 | Buy |
| ADX (14) | 31.70 | Buy |
| ATR (14) | 0.69 | Info |
The 30-day technical picture is bullish, supported by a bullish overall sentiment. The RSI is 70, indicating strong relative strength.
Key moving averages are $17.83 for the SMA50 and $14.35 for the SMA200, with near-term dynamics anchored by support at $15.34 and resistance at $22.83. The 30-day price range stretches from $18.46 to $30.58, highlighting a broad trading band in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $12.62 | $24.34 | $32.64 | 0% | Neutral | |
| $23.26 | $29.85 | $40.81 | +23% | Bullish | |
| $27.29 | $36.27 | $51.81 | +49% | Bullish | |
| $36.30 | $49.67 | $73.43 | +104% | Bullish | |
| $44.38 | $62.34 | $94.83 | +156% | Bullish | |
| $47.76 | $68.70 | $107.14 | +182% | Bullish | |
| $54.14 | $79.63 | $126.98 | +227% | Bullish | |
| $55.38 | $83.18 | $135.33 | +242% | Bullish | |
| $59.47 | $91.15 | $151.04 | +274% | Bullish | |
| $78.13 | $122.08 | $205.77 | +402% | Bullish | |
| $111.70 | $190.70 | $345.13 | +684% | Bullish | |
| $211.50 | $422.70 | $847.45 | +16.4x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $12.62 | $24.34 | $30.17 | +0.00% |
| August 2026 | $21.86 | $25.96 | $31.77 | +6.66% |
| September 2026 | $21.20 | $25.39 | $31.49 | -2.20% |
| October 2026 | $20.89 | $25.21 | $31.62 | -0.71% |
| November 2026 | $21.32 | $25.89 | $32.79 | +2.69% |
| December 2026 | $20.92 | $25.55 | $32.64 | -1.29% |
Click any year to see its month-by-month BIOA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, BIOA could reach as high as $32.64, with a base case around $24.34 and support toward $12.62 — roughly 0% from $24.34. Price action looks broadly range-bound.
Expect BIOA to range from $23.26 to $40.81 through 2027. The $29.85 average target implies a +23% move from current prices. That is up +23% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The BIOA price prediction for 2028 points to an average of $36.27 (low $27.29, high $51.81) — a potential gain of +49% on today's $24.34. Momentum favours further upside here.
In 2029, BIOA is projected to trade between $36.30 and $73.43, averaging $49.67 — a potential gain of +104% from today's $24.34. That is up +37% on the projected 2028 average. Buyers look set to stay in control over this stretch.
BioAge Labs, Inc.'s 2030 outlook centres on $62.34, within a $44.38 to $94.83 range. That is up +26% on the projected 2029 average. That marks a +156% change versus current levels. Momentum favours further upside here.
By 2031, BIOA could reach as high as $107.14, with a base case around $68.70 and support toward $47.76 — roughly +182% from $24.34. Buyers look set to stay in control over this stretch.
Expect BIOA to range from $54.14 to $126.98 through 2032. The $79.63 average target implies a +227% move from current prices. That is up +16% on the projected 2031 average. Momentum favours further upside here.
The BIOA price prediction for 2033 points to an average of $83.18 (low $55.38, high $135.33) — a potential gain of +242% on today's $24.34. Buyers look set to stay in control over this stretch.
In 2034, BIOA is projected to trade between $59.47 and $151.04, averaging $91.15 — a potential gain of +274% from today's $24.34. That is up +10% on the projected 2033 average. Momentum favours further upside here.
BioAge Labs, Inc.'s 2035 outlook centres on $122.08, within a $78.13 to $205.77 range. That is up +34% on the projected 2034 average. That marks a +402% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, BIOA could reach as high as $345.13, with a base case around $190.70 and support toward $111.70 — roughly +684% from $24.34. Momentum favours further upside here.
Expect BIOA to range from $211.50 to $847.45 through 2050. The $422.70 average target implies a +16.4x move from current prices. That is up +122% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in BIOA today (≈ 41.084634 BIOA) could be worth
$17,366.28
+$16,366.28 (+1637%) by 2050 · US Dollar
Based on the average projected BIOA price of $422.7 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BIOAwould be worth at today's price.
$1,000 invested in BIOA on Jul 10, 2025 (≈ 213.675222 BIOA) would be worth
$5,200.85
+$4,200.85 (+420.1%) today · 5.20× · US Dollar
Based on a BIOA entry price of $4.68 vs. today's $24.34.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $25.1 | $969.72 | -3.0% |
| 1 month ago | $15.48 | $1,572.35 | +57.2% |
| 3 months ago | $16.19 | $1,503.4 | +50.3% |
| 6 months ago | $17.85 | $1,363.59 | +36.4% |
| 1 year ago | $4.68 | $5,200.85 | +420.1% |
| All time (1.8y) ago | $18.31 | $1,329.33 | +32.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BIOA forecast.
Our base-case forecast reaches $49.00 around 2029.
Implied market cap at $49.00: $2.18B
The multi-year forecast shows sustained upside with a bullish tone through 2027–2050. The 2027 average is $29.01 (min $22.20, max $40.62) with ROI 22.1% and bullish sentiment; the trajectory climbs through 2028 ($35.71 avg, ROI 50.3%), 2029 ($47.39 avg, ROI 99.5%), and into 2030 ($61.35 avg, ROI 158.2%) with continued bullishness.
Beyond 2030, the forecast remains bullish, with 2031 average $67.27 (ROI 183.1%), 2032 $74.97 (ROI 215.5%), 2033 $79.63 (ROI 235.2%), and 2034 $86.14 (ROI 262.5%). By 2035 the average rises to $116.32 (ROI 389.6%), then to $182.07 by 2040 (ROI 666.3%) and finally $381.42 by 2050 (ROI 1505.3%), all with a bullish sentiment.
These projections imply substantial long-term upside, but they are estimates and not guarantees. Investors should consider the inherent uncertainty and the fact that outcomes can differ from forecasted paths.
Tap a question to reveal the answer.
2030 avg price is $61.35 with a min of $42.25 and a max of $96.58. The forecast shows an ROI of 158.2% and a bullish sentiment.
Yes, the forecast shows a bullish sentiment from 2027 onward with rising average prices and rising ROIs: 2027 avg $29.01 (ROI 22.1%), 2028 avg $35.71 (ROI 50.3%), 2029 avg $47.39 (ROI 99.5%), 2030 avg $61.35 (ROI 158.2%), 2031 avg $67.27 (ROI 183.1%), and later years showing continued upside (2040 ROI 666.3%, 2050 ROI 1505.3%). The near term (2026) is neutral with an average of $23.76.
The 2031 forecast shows a max of $108.84, which exceeds $100, while the average is $67.27. This suggests the $100 level is plausible within the projected range, though it remains an estimate.
Current price is $23.76 and the market cap is $1.06B.
The overall technical picture is bullish with RSI 70. The SMA50 is $17.83 and the SMA200 is $14.35. Support is at $15.34 and resistance at $22.83. The 30-day range spans $18.46 to $30.58 and annualized volatility is 70%.
BioAge Labs, Inc. Community Discussion
0Share your BioAge Labs, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.